Short Interest in China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Decreases By 99.4%

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) saw a large decrease in short interest during the month of August. As of August 14th, there was short interest totaling 26,461 shares, a decrease of 99.4% from the July 30th total of 4,613,535 shares. Based on an average daily trading volume, of 2,740,460 shares, the short-interest ratio is currently 0.0 days. Currently, 5.8% of the company’s stock are short sold.

China SXT Pharmaceuticals Stock Down 5.8%

SXTC traded down $0.22 during trading on Tuesday, reaching $3.58. 172,732 shares of the stock were exchanged, compared to its average volume of 399,954. China SXT Pharmaceuticals has a twelve month low of $3.10 and a twelve month high of $83,758.80. The stock’s 50 day moving average price is $102.70 and its two-hundred day moving average price is $137.58. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.94 and a quick ratio of 7.76.

China SXT Pharmaceuticals (NASDAQ:SXTC) last announced its quarterly earnings results on Wednesday, July 1st. The company reported ($5.60) EPS for the quarter. The business had revenue of $0.26 million for the quarter.

Analyst Upgrades and Downgrades

SXTC has been the topic of a number of recent research reports. Wall Street Zen raised China SXT Pharmaceuticals to a “sell” rating in a research report on Saturday. Weiss Ratings raised China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On China SXT Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. XTX Topco Ltd acquired a new position in China SXT Pharmaceuticals during the fourth quarter worth approximately $36,000. Virtu Financial LLC lifted its position in shares of China SXT Pharmaceuticals by 107.5% in the third quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock valued at $46,000 after buying an additional 15,013 shares during the last quarter. Finally, Citadel Advisors LLC bought a new position in shares of China SXT Pharmaceuticals during the 3rd quarter worth approximately $78,000. 5.02% of the stock is currently owned by institutional investors and hedge funds.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.